

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19392 A1

- (51) International Patent Classification⁷: **A61K 38/57**, 31/685, 35/42, 45/06, A61P 11/00 // (A61K 38/57, 35:42) (A61K 38/57, 38:17, 31:66) (A61K 45/06, 38:57, 38:17, 31:685, 31:683)
- (21) International Application Number: **PCT/EP99/06845**
- (22) International Filing Date:
16 September 1999 (16.09.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicants (*for all designated States except US*): **BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH** [DE/DE]; Byk-Gulden-Strasse 2, D-78467 Konstanz (DE). **CENTEON PHARMA GMBH** [DE/DE]; Emil-von-Behring-Strasse 76, D-35041 Marburg (DE).
- (72) Inventors; and
(75) Inventors/Applicants (*for US only*): **HÄFNER, Dietrich** [DE/DE]; Beethovenstr. 5, D-78464 Konstanz (DE). **GERMANN, Paul-Georg** [DE/DE]; Rotkehlchenweg 19, D-21255 Tostedt (DE). **OTT, Nils** [DE/DE]; Krielerstr. 81, D-50935 Köln (DE).
- (74) Common Representative: **BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH**; Byk-Gulden-Strasse 2, D-78467 Konstanz (DE).
- (81) Designated States (*national*): AE, AL, AU, BA, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (71) Applicants and
(72) Inventors: **VANGEROW, Burkhard** [DE/DE]; Weizenkamp 22, D-30952 Ronnenberg (DE). **RÜCK-OLDT, Horst** [DE/DE]; Schwanenring 24, D-30627 Hannover (DE). **MARX, Gernot** [DE/DE]; Hertzstrasse 9, D-30163 Hannover (DE). **COBAS MEYER, Michael** [DE/DE]; Bertha v. Suttner-Platz 2, D-30173 Hannover (DE). **LEUWER, Martin** [DE/DE]; Bleichenstrasse 81f, D-31515 Wunstorf (DE).
- Published:**
— *With international search report.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATION OF C1-INH AND LUNG SURFACTANT FOR THE TREATMENT OF RESPIRATORY DISORDERS

(57) Abstract: Pharmaceutical composition for the treatment of IRDS and ALI (including ARDS) which contains C1-INH (C1 esterase inhibitor) and lung surfactant.

BEST AVAILABLE COPY

WO 01/19392 A1

COMBINATION OF C1-INH AND LUNG SURFACTANT FOR THE TREATMENT OF RESPIRATORY DISORDERS

Technical Field

The invention relates to a novel combination and method for the treatment of disease conditions which are designated as Infant Respiratory Distress Syndrome (IRDS) and Acute Lung Injury (ALI) including Acute or Adult Respiratory Distress Syndrome (ARDS).

Prior Art

Adult Respiratory Distress Syndrome (ARDS) is a descriptive expression which is applied to a large number of acute, diffuse infiltrative pulmonary lesions of differing etiology if they are associated with a severe gas exchange disorder (in particular arterial hypoxemia). The expression ARDS is used because of the numerous clinical and pathological features common with Infant Respiratory Distress Syndrome (IRDS). If, in the case of IRDS, the lung surfactant deficiency caused by premature birth is predominant, then in the case of ARDS a lung surfactant malfunction is caused by the lung condition based on differing etiologies.

Triggering causes for ALI (Acute Lung Injury) including ARDS can, for example, be (cited in accordance with Harrison's Principles of Internal Medicine 10th Ed. 1983 McGraw-Hill Int. Book Comp.) diffuse pulmonary infections (e.g. due to viruses, bacteria, fungi), aspiration of, for example, gastric juice or in the case of near-drowning, inhalation of toxins or irritants (e.g. chlorine gas, nitrogen oxides, smoke), direct or indirect trauma (e.g. multiple fractures or pulmonary contusion), systemic reactions to inflammations outside the lung (e.g. hemorrhagic pancreatitis, gram-negative septicemia), transfusions of high blood volumes or alternatively after cardiopulmonary bypass.

With a mortality of 50-60% (survey in Schuster Chest 1995, 107:1721-26), the prognoses of an ARDS patient are still to be designated as unfavourable.

The therapy of ARDS consists mainly in the earliest possible application of different forms of ventilation [e.g. PEEP (positive end-expiratory pressure), raising of the oxygen concentration of the respiratory air, SIMV (Synchronized Intermittent Mandatory Ventilation; Harrison's Principles of Internal Medicine 10th Ed 1983 McGraw-Hill Int. Book Comp)] up to extracorporeal membrane oxygenation (ECMO; Zapol and Lemaire Adult Respiratory Distress Syndrome, Marcel Dekker Inc. 1991).

The specific use of various ventilation techniques has only led to a small lowering of mortality and includes the risk of setting in motion a vicious circle. By ventilation with pressure and high FiO_2 (Fraction of Inspired Oxygen; proportion of oxygen in the respiratory air), the lungs themselves can be damaged and as a result of this even higher pressures and higher FiO_2 may be required in order to obtain an adequate oxygenation of the blood.

Nowadays different pharmacological approaches to the solution are also followed. These include lung surfactant substitution [survey, for example B. Lachmann, D. Gommers and E.P. Eijking: Exogenous surfactant therapy in adults, *Atemw.-Lungenkrkh.* 1993, 19:581-91; T. J. Gregory et al.: Surfactant supplementation in patients with acute respiratory distress syndrome (ARDS), *Am. J. Respir. Crit. Care Med.* 1994, 149:A567] up to purely antiinflammatory therapy with, for example, prostaglandin E_1 (PGE_1 ; Abraham et al. *Crit Care Med* 1996, 24:10-15) or glucocorticosteroids (Bernard et al. *N Engl J Med* 1987, 317:1565-70). Although specific successes were achieved by the administration of lung surfactant (e.g. Walmrath et al. *Am J Resp Crit Care Med* 1996, 154:57-62), the purely antiinflammatory therapies led to few to no successes. This is in direct contrast to the pathological or histopathological findings in ARDS. Thus massive polymorphonuclear leucocyte infiltrations (survey, for example Thiel et al. *Anesthesist* 1996, 45:113-130) were found in the lungs and the lavage of patients with ARDS and a number of inflammatory mediators are detectable. In testing, PGE_1 is additionally present in a liposomal intravenous administration form (Abraham et al. *Crit Care Med* 1996, 24:10-15) as well as substances which aim at the inhibition of phosphatidic acids (e.g. Lisofylline; Rice et al. *Proc Natl Acad Sci* 1994, 91:3857-61) or recombinant human interleukin 1 (IL-1) receptor antagonists (Fisher et al. *JAMA* 1994, 271:1836-43). Both PGE_1 and the IL-1 receptor antagonist, however, are restricted in their therapeutic utility by side effects.

WO98/35683 indicates compositions for the treatment of ARDS and IRDS which contain N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide and lung surfactant. WO96/09831 indicates compositions for the treatment of ARDS and IRDS which contain a glucocorticosteroid and lung surfactant. EP-B-0 451 215 describes compositions for the administration of a pharmaceutical active compound via the lungs. These compositions include liposomes which contain a pharmaceutical active compound and a lung surfactant protein. EP-B-0 055 041 describes preparations for inhalation or infusion for the treatment of disorders of the respiratory organs, which contain an active compound against disorders of the respiratory organs and natural lung surfactant. Compositions for the treatment of ARDS and IRDS are not disclosed.

Description of the Invention

It has now surprisingly been found that by the administration of a combination of C1-inhibitor and lung surfactant a synergistic effect can be achieved in the treatment of IRDS and ALI, including ARDS.

In a first aspect the invention relates to a pharmaceutical composition for the treatment of IRDS and ARDS comprising C1-inhibitor in combination with lung surfactant.

Further embodiments of the invention follow from the Patent Claims.

In connection with the invention C1-inhibitor (hereinafter also referred to as C1-INH) refers to a protein, designated C1-inhibitor according to the ability to inhibit e.g. C1-esterase of the complement system and the bradykinin/kinin system. C1-inhibitor can be prepared by isolation from blood plasma according to methods known in the art. A process for production of C1-inhibitor for therapeutic purposes for example is disclosed in EP 0 101 935. A commercially available product comprising C1-inhibitor which may be mentioned is Berinert® HS [Centeon Pharma, Marburg (Lahn), Germany]. Berinert® is used in connection with the treatment of hereditary angioedema and congenital deficiency.

Lung surfactant is understood according to the invention as meaning the numerous known compositions and their modifications which have the function of natural lung surfactant. Natural lung surfactant has surface-active properties and reduces the surface tension in the alveolar region of the lungs. A simple and rapid quantitative in vitro assay to determine the surface activity of a surfactant preparation is e.g. the Wilhelmy balance [Goerke, J Biochim Biophys Acta, 344:241-261 (1974); King R.J. and Clements J.A., Am J Physiol 223:715-726 (1972)]. It gives an indication of surfactant quality in terms of the ability to approach a surface tension of near zero mN/m. It is performed by injecting a surfactant suspension at defined concentrations of phospholipids into a hydrous solution. The phospholipids spread to the air-liquid phase building a so-called monolayer. This monolayer reduces the surface tension of the hydrous solution. A platinum plate is carefully dipped into the solution. Now the force which pulls down the platinum plate can be measured with sensitive transducers. This force is proportional to the surface tension and depends on the dimensions of the platinum plate. An other method to describe the surface activity of surfactant preparations is the pulsating bubble surfactometer [Possmayer F., Yu S. and Weber M., Prog Resp Res, Ed.v. Wichert, Vol. 18:112-120 (1984)]. The activity of a surfactant preparation can also be assessed by an in vivo assay, for example, as described below in the section Pharmacology or in an assay as described by Häfner et al. (D. Häfner et al.: Effects of rSP-C surfactant on oxygenation and histology in a rat lung lavage model of acute lung injury. Am. J. Respir. Crit. Care Med. 1998, 158: 270-278). Measurement of lung compliance, blood gases and ventilator pressure will provide indices of activity.

Lung surfactant is to be understood according to the invention preferentially as compositions which will show activity in such an assay. Particular mention may be made of compositions which will show an activity in such an assay similar or greater to that of natural, in particular human, lung surfactant.

In particular lung surfactant compositions comprise phospholipids and inter alia can additionally contain lung surfactant proteins. Preferred phospholipids which may be mentioned in connection with the invention are dipalmitoylphosphatidylcholine (DPPC), palmitoyloleoylphosphatidylglycerol (POPG) and/or phosphatidylglycerol (PG). Preferably the phospholipids are mixtures of dipalmitoylphosphatidylcholine (DPPC) and palmitoyloleoylphosphatidylglycerol (POPG), in particular in a ratio from 7 to 3, to 3 to 7. Possible lung surfactant proteins are both the proteins obtained from natural sources, such as, for example, pulmonary lavage or extraction from amniotic fluid, and also synthetically or genetically engineered proteins. According to the invention, the lung surfactant proteins designated by SP-B and SP-C and their modified derivatives are particularly of interest. The amino acid sequences of these lung surfactant proteins, their isolation or preparation by genetic engineering are known (e.g. from WO-86/03408, EP-A-0 251, 449, WO-89/04326, WO-87/06943, WO-88/03170, EP-A-0 368 823 and EP-A-0 348 967). Modified derivatives of SP-C which differ from human SP-C by replacement of certain amino acids are disclosed for example in WO91/18015 and WO95/32992. Particular mention may be made of the SP-C derivatives disclosed in WO95/32992. According to the invention surfactant protein in particular refers to a recombinant SP-C derivative [hereinafter referred to as r-SP-C or r-SP-C (FF/I)] which differs from human SP-C by replacement of the two cysteines in position 4 and 5 by phenylalanine and replacement of the methionine in position 32 by isoleucine. The term lung surfactant protein as used herein also refers to mixtures of different lung surfactant proteins.

Further components which may be present in lung surfactant compositions are fatty acids, for example palmitic acid. The lung surfactant compositions may also contain electrolytes such as calcium, magnesium and/or sodium salts (for example calcium chloride, sodium chloride and/or sodium hydrogen carbonate), to set a favourable viscosity. The skilled worker will base his determination of the type and amount of individual constituents of the lung surfactant composition on the one hand on the known composition of natural pulmonary surfactant, and on the other hand on the numerous proposals in the prior art, such as for example, EP-A 0119056 and EP-A 0406732.

EP-B-0 100 910, EP-A-0 110 498, EP-B-0 119 056, EP-B-0 145 005 and EP-B-0 286 011 describes phospholipid compositions with and without lung surfactant proteins which are suitable, for example, as components of the preparations according to the invention.

Commercially available products which may be mentioned are Curosurf® (Serono, Pharma GmbH, Unterschleissheim), a highly purified natural surfactant from homogenized pigs' lungs, Survanta® (Abbott GmbH, Wiesbaden) and Alveofact® (Dr. Karl Thomae GmbH Biberach), both extracts of bovine

lungs, and also Exosurf® (Deutsche Wellcome GmbH, Burgwedel), a synthetic phospholipid with auxiliaries.

Lung surfactant compositions in connection with the invention expediently contain 80 to 95 % by weight of phospholipids, 0.2 to 5 % by weight of surfactant protein, 2 to 15 % by weight of fatty acids and 0 to 5 % by weight of electrolytes (of the dry mass).

Preferred lung surfactant compositions in connection with the invention contain 80 to 95 % by weight of phospholipids, 0.5 to 3.0 % by weight of surfactant protein, 3 to 15 % by weight of fatty acids and 0 to 3 % by weight of calcium chloride (of the dry mass).

Particularly preferred lung surfactant compositions in connection with the invention contain 80 to 95 % by weight of phospholipids, 0.5 to 3.0 % by weight of surfactant protein, 4 to 7 % by weight of fatty acids, preferably palmitic acid and 1 to 3 % by weight of calcium chloride (of the dry mass).

In connection with the invention combination means fixed, and free combinations, i.e. either C1-INH and lung surfactant are present together in one dosage unit, or C1-INH and lung surfactant, which are present in separate dosage units, are administered in direct succession or at a relatively large time interval; a relative large time interval means a time span up to a maximum of 24 hours. For use as separate dosage units, these are preferably made available together in one pack.

Separate dosage units for lung surfactant and C1-INH are prepared by procedures familiar to those skilled in the art, if appropriate using further suitable pharmaceutical auxiliaries. Preferably C1-INH is present in lyophilized form in connection with separate dosage units. A suitable product is known in the art under the trademark Berinert® HS. The preparation of a lung surfactant composition can be achieved by methods known to those skilled in the art, for example by incorporation of a surfactant protein into a phospholipid matrix, for example as described in WO95/32992. In connection with the invention, the lung surfactant compositions are made available preferably in lyophilized form and in particular in spray dried form. Lyophilized compositions are for example known from WO97/35882, WO95/32992, WO91/00871 and DE 3229179. WO97/26863 describes a process for the production of a lung surfactant composition in powder form by means of spray drying.

In connection with fixed combinations, the compositions according to the invention are prepared by procedures familiar to those skilled in the art, if appropriate using further suitable pharmaceutical auxiliaries. A powder form is obtained, for example, by directly mixing powdered forms of C1-INH and lung surfactant or by mixing liquid lung surfactant preparations, e.g. aqueous suspensions, with aqueous solutions of C1-INH and then lyophilizing and micronizing it. Alternatively, a solution of a lung surfactant and C1-INH can be lyophilized in a suitable solvent, such as, for example, isopropanol, and then micronized. Spray-drying of a mixture of an aqueous lung surfactant suspension and an aqueous C1-INH

solution or a solution of a lung surfactant and C1-INH in suitable solvents, such as alcohols, (e.g. methanol, ethanol, 2-propanol) chloroform, dichloromethane, acetone and their mixtures, which optionally can additionally contain water may also leads to powdered preparations.

Pharmacology

Materials and Methods

Animal Preparation

The study protocol was reviewed and approved by the Laboratory Animal Care Committee at the district presidency of Freiburg, Germany in accordance with guidelines for ethical animal research. The study was performed with a total of 36 male Sprague Dawley rats (Harlan CBP, Zeist, The Netherlands), with a body weight (b.w.) of 242-264 g.

After induction of general anesthesia with halothane and nitrous oxide in oxygen an indwelling catheter was placed into one carotid artery. After intraperitoneal (i.p.) injection of pentobarbital (60 mg/kg b.w.) the rats were tracheotomized and a tube was secured into the trachea of each animal. Before mechanical ventilation was started the animals received an intramuscular (i.m.) injection of pancuronium bromide (2 mg/kg b.w.). The tracheal tubes of six animals were connected to a distributor and animals were ventilated simultaneously using a Servo 900 C ventilator (Siemens Elema, Solna, Sweden) at a respiratory rate of 30 breaths/min, a fraction of inspired oxygen (FiO_2) of 1.0, an inspiration / expiration ratio of 1:2, a peak inspiratory pressure (PIP) of 15 cm H_2O and a positive end-expiratory pressure (PEEP) of 2 cm H_2O . Additional pentobarbital (i.p., 15 mg/kg b.w.) and pancuronium bromide (i.m., 2 mg/kg b.w.) were given when appropriate.

C1-Inhibitor

Pasteurized human C1-Inhibitor (Berinert® HS, Centeon, Germany) was resuspended with 9 ml physiological (0.9%) saline solution to achieve a concentration of 50 units (U)/ ml. One unit is the amount of C1-INH present in 1 ml of normal human plasma (equal to 270 μ g). Animals treated with C1-Inhibitor received 200 U/kg b.w. intraarterially.

Surfactant

r-SP-C surfactant (Byk Gulden, Germany) contains 2% recombinant surfactant protein C (r-SP-C is an analog of human SP-C that has phenylalanine instead of two cysteines in positions 4 and 5 of the human SP-C sequence, and isoleucin in position 32 instead of methionine) embedded in a phospholipid matrix. It consists of dipalmitoylphosphatidylcholine and palmitoyloleoylphosphatidylglycerol at a ratio of 70:30 plus 5% (w/w) palmitic acid as related to phospholipids (PL). The r-SP-C surfactant was resuspended with physiological (0.9%) saline solution to achieve a concentration of 25 mg PL per ml. Surfactant was instilled intratracheally (i.t.) as bolus of 25 mg PL per kg body weight in a volume of 1.2 ml per animal. The r-SP-C surfactant was diluted with 0.9% saline solution to achieve the required concentration of 6.25 mg total PL per 1.2 ml.

Experimental Protocol

After instrumentation, blood samples were withdrawn from the arterial catheter for baseline determination of blood gases and C1-INH levels. Only animals with PaO_2 values of more than 480 mmHg were included in the experiments. Peak inspiration pressure (PIP) was raised to 28 cm H_2O and PEEP to 8 cm H_2O and the animals were subjected to multiple lung lavage (6-8 times) with 1 ml/30 g b.w. of isotonic saline solution. To avoid metabolic acidosis, 4 ml/kg b.w. of a glucose/ NaHCO_3 solution (5g glucose-monohydrate and 8.4g NaHCO_3 dissolved in 100 ml 0.9% NaCl solution) were given by i.p. injection to each animal after lavage. Administration of glucose/ NaHCO_3 was repeated if arterial HCO_3^- decreased below 20 mmol/l during the experiment. Blood gases were determined at 5, 30, and 60 min after the last lavage using an ABL-500 blood gas analyzer (Radiometer, Copenhagen, Denmark). Only animals with PaO_2 values between 50 and 110 mmHg after the lavage procedure were included in the study.

Four experimental groups and two control groups were studied: In group 1 the animals were sacrificed one hour after the last lavage and in group 2 the animals were sacrificed at 210 min after the last lavage and these animals did not receive any treatment. In group 3 C1-INH (200 U/kg b.w.) was administered 60 minutes after the last lavage (p.l.). In group 4 the animals received 25 mg/kg b.w. r-SP-C surfactant at 60 min. p.l.. In group 5 the animals were treated with C1-INH and r-SP-C surfactant at 60 min. p.l.. In group 6 C1-Inhibitor was administered at 10 min. p.l.. Subsequently, blood gases were determined 90, 120, 150, 180 and 210 min after the last lavage. During the whole experimental period PIP and PEEP were kept constant at 28 cm H_2O and 8 cm H_2O , respectively. The animals were sacrificed at 210 minutes after the last lavage procedure.

Preparation of the lungs

The lungs were carefully excised en bloc and fixed for 24 h in 8% phosphate-buffered formalin. Following fixation blocks of all lobes were sectioned and stained with haematoxylin and eosin (HE). After randomization and codification each section was examined under light microscopy. Hyaline membrane formation was assessed semiquantitatively according to the previously used technique (D. Häfner et al.: Effects of rSP-C surfactant on oxygenation and histology in a rat lung lavage model of acute lung injury. *Am. J. Respir. Crit. Care Med.* 1998, 158: 270-278). The severity of hyaline membrane formation was graded 0 to 4+ (0, no hyaline membrane formation; 1+, occasional fields showing hyaline membrane formation in a low number (1-3) of membranes per viewed field (minimal); 2+, occasional fields showing hyaline membrane formation in an increased number (>3) of membranes per viewed field (mild); 3+, many but not all fields showing hyaline membrane formation (moderate); 4+, hyaline membrane formation in all fields examined (severe)). The distribution and severity of intraalveolar accumulation of PMNL's were graded semiquantitatively from 0 to 4+ comparable to the grading of hyaline membrane formation but with respect to the number of inflammatory cells and the location of these cells. The severity of intra-alveolar and perivascular hemorrhage were graded semiquantitatively using the same scale from 0 to 4+.

Sampling procedure and C1-INH assay

Blood samples for C1-INH determination were obtained at baseline and at 210 min. p.l. from the arterial catheter and placed into plastic tubes containing 3.8% sodium citrate. Plasma was obtained from blood samples centrifuged for 15 minutes at 2.500 g. All samples were stored at minus 70° Celsius. The activity of C1-Inhibitor was measured by an amidolytic method using an excess of C1-Esterase and C₂H₅Co-Lys(E-Cbo)-Gly-Arg-pNa as substrate (Berichrom C1-INH, Behring Diagnostics, Marburg, Germany). In this assay C1-INH inhibits cleavage of the chromogenic substrate by C1-Esterase. C1-INH activity of the samples was calculated from a reference curve prepared from human standard plasma.

Statistics

Results are presented as mean \pm standard deviation. Overall variations during the study protocol were analyzed using Kruskal-Wallis tests (nonparametric one-way analysis of variance). Subsequent comparisons between groups were analyzed using Wilcoxon tests and adjusted for multiple testing. All tests were two-tailed and a $p < .05$ was considered statistically significant.

Results

Oxygenation

The arterial oxygen tension decreased from 530 ± 14 mmHg (baseline) to 84 ± 10 mmHg after the lavage procedure. No animal of the control group showed a spontaneous increase in arterial pO₂ during the experimental period. Arterial pO₂ increased significantly to 496 ± 54 mmHg in group 4 (r-SP-C surfactant) and to 446 ± 65 mmHg in group 5 (r-SP-C surfactant and C1-INH) at 30 minutes and remained high until sacrifice. PaO₂ values of animals treated with C1-Inhibitor only were comparable to controls with a tendency towards higher paO₂ values in animals receiving C1-INH at 60 minutes postlavage. Figure 1 summarizes the effects of C1-INH and r-SP-C surfactant administration on arterial pO₂.

C1-Inhibitor

Baseline levels of C1-Inhibitor activity were 44 ± 12 % of human standard plasma. In the groups treated with C1-INH concentrate (group 3, 5 and 6), plasma levels increased to 210 ± 41 %. In the control groups (group 1 and 2) and animals treated with r-SP-C surfactant only (group 4) C1-INH activity remained at 36 ± 14 %.

Histopathological evaluation

The gradings for the observed histopathological changes are presented in figure 2. In untreated controls only moderate hyaline membrane formation was present in the lungs at 60 minutes after the last lavage. The mean severity of hyaline membrane formation increased during the experiment from 2.50 at 60 minutes p.l. up to 3.16 at sacrifice. In addition to that, the grading for intravascular and intraalveolar granulo-

cytes (margination of polymorphonuclear neutrophil leukocytes, PMNL), the intraalveolar bleedings and the formation of edema showed a similar time-dependant increase.

At 210 minutes after lavage, the formation of hyaline membranes was significantly reduced in group 3 (r-SP-C surfactant, see figure 2). The combination of r-SP-C surfactant with C1-INH (group 4) and C1-INH monotherapy 60 minutes after lavage (group 5) showed a comparable effect on the prevention of hyaline membrane formation to r-SP-C surfactant monotherapy (figure 2). C1-INH administration at 10 minutes after lavage (group 6) had only a minor effect on the prevention of hyaline membrane formation (figure 2). The intratracheal application of r-SP-C surfactant (group 3) lead to an increase in the histopathological gradings for intravascular and intraalveolar granulocytes, for intraalveolar bleedings and edema in comparison to the particular mean severity gradings of the 210 minutes control group (group 2) as shown in figure 2. The observed histopathological changes after r-SP-C surfactant monotherapy were less severe when r-SP-C surfactant was combined with C1-INH (figure 2). C1-Inhibitor monotherapy (group 5 and 6) reduced significantly the histopathological gradings for intravascular and intraalveolar granulocytes, for intraalveolar bleedings and edema formation (figure 2).

In the investigation of compositions according to the invention comprising C1-INH and lung surfactant in this model, it was found that the oxygenation and the histological changes improve synergistic in comparison with the sole administration of lung surfactant or C1-INH. Based on this unexpected result it can be concluded that by using a combination of C1-INH and lung surfactant the treatment of IRDS and ALI (including ARDS) can be shortened and the high mortality accompanying these syndromes can be reduced. Additionally it is possible either to save a portion of the very expensive LSF or to attain an enhanced effect of each of the components.

Commercial Utility

Adult Respiratory Distress Syndrome (ARDS) is a descriptive expression which is applied to a large number of acute, diffuse infiltrative pulmonary lesions of differing etiology if they are associated with a severe gas exchange disorder (in particular arterial hypoxemia). The expression ARDS is used because of the numerous clinical and pathological features common with Infant Respiratory Distress Syndrome (IRDS). If, in the case of IRDS, the lung surfactant deficiency caused by premature birth is predominant, then in the case of ARDS a lung surfactant malfunction is caused by the lung condition based on differing etiologies.

Triggering causes for ALI (Acute Lung Injury) including ARDS can, for example, be (cited in accordance with Harrison's Principles of Internal Medicine 10th Ed. 1983 McGraw-Hill Int. Book Comp.) diffuse pulmonary infections (e.g. due to viruses, bacteria, fungi), aspiration of, for example, gastric juice or in the case of near-drowning, inhalation of toxins or irritants (e.g. chlorine gas, nitrogen oxides, smoke), direct or indirect trauma (e.g. multiple fractures or pulmonary contusion), systemic reactions to inflammations outside the lung (e.g. hemorrhagic pancreatitis, gram-negative septicemia), transfusions of high blood volumes or alternatively after cardiopulmonary bypass.

The compositions according to the invention are not only suitable for the treatment or prophylaxis of IRDS in premature babies and for the treatment or prophylaxis of ALI including ARDS in adults in particular in connection with multiple organ failure, but also for the treatment or prophylaxis of pneumonia, bronchitis, meconium aspiration syndrome, COPD (chronic obstructive pulmonary disease), asthma and cystic fibrosis.

The administration of the compositions according to the invention is accomplished according to methods known by those skilled in the art. Preferably the compositions according to the invention are dissolved or resuspended in a suitable solvent or resuspension medium for administration. This is particularly preferred in case of spray dried or lyophilized compositions. Preferably physiological saline solution is used as suitable resuspension medium. It may be advantageous to administer suspensions or solutions of the compositions according to the invention which contain from 6,25 to 100 mg phospholipids per ml suspension or solution. It is preferred to administer (per single administration) suspensions or solutions of the compositions according to the invention which contain from 6,25 to 200 mg phospholipids and from 1 to 600 IU mg C1-INH per kg body weight. In connection with pulmonary application it is preferred to administer from 1 to 60 IU C1-INH per kg body weight and in connection with systemic application it is preferred to administer from 6 to 600 IU C1-INH per kg body weight. Expediently the compositions are administered one to three times a day, for a period from one to seven days. In connection with systemic application of the C1-INH it is preferred to administer 6 to 600 IU C1-INH per kg body weight as bolus and 3 to 300 IU C1-INH per kg body weight per day as continuous infusion for the next three to four days.

In connection with fixed combinations the administration of the pharmaceutical composition is preferably accomplished by intratracheal instillation (infusion or bolus) or by way of atomization.

In connection with free combinations the administration of the lung surfactant composition is preferably accomplished by intratracheal instillation (infusion oder bolus) or by way of atomization and the administration of the C1-INH composition is preferably accomplished by injection or infusion. In case of separate dosage units, C1-INH and lung surfactant are administered in direct succession or at a relatively large time interval; a relative large time interval means a time span up to a maximum of 24 hours.

If desired, prior to administration of the compositions according to the invention a bronchoalveolar lavage, preferably with diluted lung surfactant suspension, can be carried out. Such a treatment is for example described by Gommers et al. [Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS), Intensive Care Med. 1998, 24:494-500] and in WO98/49191.

The invention furthermore relates to a method for the treatment of mammals, including humans, who are suffering from pneumonia, bronchitis, meconium aspiration syndrome, COPD (chronic obstructive pulmonary disease), asthma, cystic fibrosis, IRDS and/or ALI (including ARDS). The method is characterized in that a therapeutically active and pharmacologically effective and tolerable amount of the composition according to the invention is administered to the sick mammal.

The invention further relates to the use of a composition according to the invention for the production of medicaments for the treatment of pneumonia, bronchitis, meconium aspiration syndrome, COPD (chronic obstructive pulmonary disease), asthma, cystic fibrosis, IRDS and/or ALI (including ARDS).

Further subject of the invention is an article of manufacture comprising customary secondary packaging material and a pharmaceutical composition in a suitable primary packaging material (for example an ampoule or vial) contained within the secondary packaging material, wherein the pharmaceutical composition comprises C1-INH in combination with lung surfactant, optionally together with suitable pharmaceutical auxiliaries (for example saline solution for resuspension of active agents in case of powdered forms), and wherein the primary and/or secondary packaging material comprises a label or package insert which indicates that the pharmaceutical composition is useful for preventing or treating pneumonia, bronchitis, meconium aspiration syndrome, COPD (chronic obstructive pulmonary disease), asthma, cystic fibrosis, IRDS and/or ALI (including ARDS). The secondary packaging material, the primary packaging material and the label or package insert may comply with what is considered as standard for pharmaceutical compositions of this kind by those skilled in the art.

Figure Legends

Figure 1: Time course of PaO₂ [mean ± SD] in the experimental groups. C1-INH: 200 U / kg b.w. C1-INH applied intraarterially. LSF: 25 mg / kg b.w. r-SP-C surfactant applied intratracheally.

Figure 2: Histopathological grading for hyaline membrane formation, neutrophil infiltration, bleedings and edema. Data are presented as mean severity grades of all six individual animals per group after coded histopathological evaluation. C1-INH: 200 U / kg b.w. C1-INH applied intraarterially. LSF: 25 mg / kg b.w. r-SP-C surfactant applied intratracheally.

Patent Claims

1. A pharmaceutical composition for prophylaxis or treatment of IRDS and ALI (including ARDS) comprising C1-INH in combination with lung surfactant.
2. A pharmaceutical composition as claimed in claim 1, wherein C1-INH and lung surfactant are present in a fixed combination.
3. A composition as claimed in claim 1, wherein, as lung surfactant, mixtures of phospholipids are contained.
4. A composition as claimed in claim 3, wherein phospholipids occurring in natural lung surfactant are contained.
5. A composition as claimed in claim 3 or 4, wherein lung surfactant protein is additionally contained.
6. A composition as claimed in claim 5, wherein SP-B and/or SP-C and/or their modified derivatives are contained.
7. A composition as claimed in claim 1, wherein lung surfactants obtained by pulmonary lavage are contained.
8. The use of a composition according to claim 1 for the production of medicaments for the treatment of pneumonia, bronchitis, meconium aspiration syndrome, COPD (chronic obstructive pulmonary disease), asthma, cystic fibrosis, IRDS and/or ALI (including ARDS).
9. Article of manufacture comprising customary secondary packaging material and a pharmaceutical composition in a suitable primary packaging material contained within the packaging material, wherein the pharmaceutical composition comprises C1-INH in combination with lung surfactant, optionally together with suitable pharmaceutical auxiliaries and wherein the primary and/or secondary packaging material comprises a label or package insert which indicates that the pharmaceutical composition is useful for preventing or treating pneumonia, bronchitis, meconium aspiration syndrome, COPD (chronic obstructive pulmonary disease), asthma, cystic fibrosis, IRDS and/or ALI (including ARDS).

Figures

Fig. 1:





Figure 2:

2/2



A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/57 A61K31/685 A61K35/42 A61K45/06 A61P11/00
 //(A61K38/57,35:42),(A61K38/57,38:17,31:66),(A61K45/06,38:57,
 38:17,31:685,31:683)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 22320 A (GENENTECH INC) 23 December 1992 (1992-12-23)	1,2,9
Y	page 28, line 34 -page 29, line 17 ---	1-9
Y	WO 90 07469 A (BENSON BRADLEY J ;WRIGHT JORAE (US)) 12 July 1990 (1990-07-12) cited in the application page 19, line 4 -page 19, line 30 ---	1-9
Y	WO 96 09831 A (BYK GULDEN LOMBERG CHEM FAB) 4 April 1996 (1996-04-04) cited in the application page 1, line 26 -page 1, line 28 ---	1-9
Y	WO 98 35683 A (BYK GULDEN LOMBERG CHEM FAB) 20 August 1998 (1998-08-20) cited in the application page 2, line 32 -page 2, line 34 ---	1-9
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 May 2000

Date of mailing of the international search report

23/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/06845

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 055 041 A (TEIJIN LTD) 30 June 1982 (1982-06-30) cited in the application page 2, line 31 -page 3, line 7 page 4, line 19 -page 4, line 21 ----	1-9
A	WALMRATH ET AL: "Therapie des ARDS" INTENSIVMEDIZIN UND NOTFALLMEDIZIN, vol. 36, no. 2, 1999, pages 104-125, XP000856579 page 108, right-hand column, line 3-10 page 122, left-hand column, paragraph 2 -----	1-9

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1, 2, 5-9 relate to a composition and use thereof defined (inter alia) by reference to the following parameters: "lung surfactant", "lung surfactant protein", or "modified derivatives" thereof.

The use of these parameters in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the compounds specifically disclosed in the claims and any examples, with due regard to the description and the general idea underlying the invention.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9222320 A	23-12-1992	NONE	
WO 9007469 A	12-07-1990	US 5006343 A AT 109971 T AU 638903 B AU 5092590 A CA 2006956 A DE 68917603 D DE 68917603 T EP 0451215 A HK 1006806 A HU 211244 B JP 2954343 B JP 4503953 T	09-04-1991 15-09-1994 08-07-1993 01-08-1990 29-06-1990 22-09-1994 16-03-1995 16-10-1991 19-03-1999 28-11-1995 27-09-1999 16-07-1992
WO 9609831 A	04-04-1996	DE 4434629 C AU 705099 B AU 3742895 A BG 62556 B BG 101441 A CA 2201377 A CZ 9700940 A EP 0783314 A FI 971277 A HU 77931 A JP 10506119 T NO 971403 A NZ 294587 A PL 319608 A SK 40197 A US 5891844 A	27-06-1996 13-05-1999 19-04-1996 29-02-2000 30-09-1997 04-04-1996 17-09-1997 16-07-1997 27-05-1997 30-11-1998 16-06-1998 17-04-1997 28-07-1998 18-08-1997 04-02-1998 06-04-1999
WO 9835683 A	20-08-1998	DE 19705924 A AU 6497398 A EP 0977577 A NO 993875 A	27-08-1998 08-09-1998 09-02-2000 11-08-1999
EP 0055041 A	30-06-1982	JP 1511337 C JP 57095920 A JP 63004812 B DE 3173589 D US 4571334 A	09-08-1989 15-06-1982 01-02-1988 06-03-1986 18-02-1986

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.